Carolyn Vachani, RN, MSN, AOCN
Abramson Cancer Center of the University of Pennsylvania
Last Modified: September 7, 2010
In the center of every cell in your body is a region called the nucleus. The nucleus contains your DNA (deoxyribose nucleic acid), which is the genetic code you inherited from each of your parents. The DNA is ribbon-like in structure, but normally exists in a condensed form called chromosomes. You have 46 chromosomes, which are in turn comprised of thousands of genes. These genes encode instructions on how to make proteins. Proteins make up the majority of a cell's structure and perform most life functions. Genes tell cells how to work, control our growth and development, and determine what we look like and how our bodies work. They also play a role in the repair of damaged cells and tissues. Each person has more than 30,000 genes, which are made up of DNA . You have 2 copies of every gene, 1 inherited from your mother and 1 from your father.
So, now that we know what genes are, how can they be used to help fight cancer? If a gene becomes damaged, this damage is called a mutation. This can lead to a gene not functioning properly and a cell growing uncontrollably. This can eventually lead to cancer formation. (Keep in mind that developing a cancer is not quite as simple as this, but probably requires a complex series of multiple mutations.) These mutations may be caused by things like smoking and/or the environment, or they may be inherited. It makes sense that if we could repair these mutations, we could potentially stop a cancer from starting. The question is, how do we do this?
Researchers are testing several ways of applying gene therapy to the treatment of cancer:
Gene delivery is one of the biggest challenges to successful gene therapy. You can imagine it would be hard to actually inject these genes into the tiny cells, so a carrier, or a "vector," is used to accomplish this. Typically, viruses are used as the vectors. The virus vector must be genetically altered to carry human DNA. These viruses are like those that cause the common cold, only they are "deactivated" so that they will not cause the patient to actually get the cold. In some cases, some cells are taken from the patient and the virus is exposed to the cells in the laboratory. The virus with the desired gene attached finds its way into the cells. These cells are allowed to grow in the laboratory, and are then given back to the patient by intravenous (IV) infusion or are injected into a body cavity (i.e. the lung) or a tumor. In other cases, the vector with the attached gene is directly inserted into the patient by intravenous infusion or is injected into a body cavity or a tumor. Once the gene has reached the cell, it must go to the cell's nucleus and become integrated within the human genetic material. Then it needs to be "turned on," to produce the protein product encoded by the gene. For gene delivery to be successful, the protein that is produced must function properly.
Gene therapy is still experimental, so the means by which it is given may change as the technology develops. The diagram below shows gene therapy using a virus vector (adenovirus is a type of cold virus).
Given that gene therapy is so new, we do not know what side effects it may have, particularly long-term side effects that may occur years after receiving this therapy. After initially receiving a type of gene therapy, the patient's immune system may react to the foreign vector, causing fever, severe chills (rigors), drop in blood pressure, nausea, vomiting, and headache. These symptoms typically resolve within 24-48 hours of the infusion. Other side effects are dependent upon the type of vector used and how it is given. If the gene is given into a patient's lung, the side effects may affect the lung.
Some side effects are theoretical, meaning that it is feasible that they could happen, yet they have not actually occurred in clinical trials to date. There is a fear that the genes could enter healthy cells, causing damage to them, which could then lead to another disease or another cancer. If genes enter reproductive cells, they could potentially cause damage to sperm or eggs. It is feared that this damage could then be passed on to future generations. At this time, researchers are particularly careful to monitor for these unwanted complications, and perform tests in animal studies before any particular therapy is given to humans.
Jul 22, 2014 - A novel gene therapy for glioblastoma multiforme utilizing a combination of adenoviral vectors and the drug ganciclovir is nearing clinical trial with the discovery of a biomarker to gauge tumor response to the treatment, according to a study reported in the July 1 issue of Clinical Cancer Research.
Jul 22, 2014